

3. AML Academy 2020

Study Alliance Leukemia – AML Cooperative Group – CELL

12th/13th November 2020



Thursday, 12th November 2020

AML Academy I

Highlights from Translational Research

13:45 – 14:05	Properties of leukemic stem cells and how to exploit them	Lengerke
14:15 – 14:35	Gene expression profiling and nanopore sequencing – the future in AML diagnostics?	Herold
14:45 – 15:05	Targeting AML with Immunocytokines	Schliemann
15:15 – 15:35	Clinical Proteomics in AML	Oellerich

AML Academy II

New Standards and the AML Development Pipeline

16:15 – 16:35	Targeted agents	Vyas
16:45 – 17:15	CAR-T cells	Hudecek
17:30 – 18:00	Post-remission treatment	Roboz
18:15 – 18:45	My current practice and future scenarios of AML treatment	Konopleva

Prof. Dr. Claudia Lengerke,
Universitätsklinikum Tübingen

PD Dr. Tobias Herold,
Klinikum der Universität München

Prof. Dr. Christoph Schliemann,
Universitätsklinikum Münster

Prof. Dr. Thomas Oellerich,
Universitätsklinikum Frankfurt

Prof. Dr. Paresh Vyas,
University of Oxford

Prof. Dr. Michael Hudecek,
Universitätsklinikum Würzburg

Prof. Dr. Gail Roboz,
Cornell University New York

Prof. Dr. Marina Konopleva,
MD Anderson Cancer Center Houston Texas

Friday, 13th November 2020

SAL Steering Committee Meeting

08:00 – 10:00

Joint Study Group Meeting of SAL, AML-CG

10:30 – 12:00 Updates on current, past and future projects and trials

Lunch Break

13:00 – 15:00 Updates on current, past and future projects and trials

Veranstalter:
GWT-TUD GmbH
Freibergerstr. 33
01067 Dresden

Online via
Go-To-Meeting

Registration:
www.xing-events.com/salh

Hauptsponsoren

